Lilly drops CVS as drug benefits manager — reportnews2025-11-12T20:08:40+00:00November 12th, 2025|Endpoints News|
Chinese biotechs are shedding their fast-follower reputations as innovation surgesnews2025-11-12T18:18:10+00:00November 12th, 2025|Endpoints News|
WuXi AppTec plants ‘flag down’ in Europe with new Munich headquarters news2025-11-12T17:39:33+00:00November 12th, 2025|Endpoints News|
Immatics shares early bispecific data as it seeks to make its name beyond cell therapynews2025-11-12T16:42:44+00:00November 12th, 2025|Endpoints News|
FDA taps Richard Pazdur as new CDER director after Tidmarsh’s resignationnews2025-11-11T21:51:07+00:00November 11th, 2025|Endpoints News|
Why class competition hasn’t brought checkpoint inhibitor prices downnews2025-11-11T19:25:52+00:00November 11th, 2025|Endpoints News|
Top biopharma execs set to appear at MAHA Summitnews2025-11-11T19:12:13+00:00November 11th, 2025|Endpoints News|
Nine takeaways from our first-ever Health Tech Daynews2025-11-11T16:39:27+00:00November 11th, 2025|Endpoints News|
CDMOs don’t expect immediate impact from ‘most favored nation’ dealsnews2025-11-11T16:04:01+00:00November 11th, 2025|Endpoints News|
Voyager, Transition Bio’s small molecule drug pact; CRISPR Therapeutics ends work on a CAR-T therapynews2025-11-11T15:41:06+00:00November 11th, 2025|Endpoints News|
